NewsBenzingaEyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint Eyepoint Says Topline Results From Lucia Phase 3 Trial Of Duravyu (Vorolanib Intravitreal Insert) For Wet Age-Related Macular Degeneration Did Not Achieve The Primary Endpoint Benzinga 2026.10.19 11:07 (GMT+0) Open on Benzinga Other news Tech Stocks Lead Broad Market Lower as Meta Slides -6% Uniswap Aggregator Hooks Go Live on Ethereum, Base and Robinhood Chain Dear Western Digital Stock Fans, Mark Your Calendars for October 22 Claude Duet app is Anthropic’s bet on agents Fireblocks Denies Report of Visa Talks for $2.5B Acquisition, Says Claim Is Untrue Meta (META) Stock Falls 7.02% Intraday, Now at $651.61
